Lifestyle Interventions in Treatment-Resistant Hypertension
Status: | Recruiting |
---|---|
Conditions: | High Blood Pressure (Hypertension) |
Therapuetic Areas: | Cardiology / Vascular Diseases |
Healthy: | No |
Age Range: | 35 - Any |
Updated: | 12/7/2018 |
Start Date: | June 2015 |
End Date: | December 2019 |
Contact: | James A. Blumenthal, PhD |
Email: | blume003@mc.duke.edu |
Phone: | 919-684-3828 |
Treating Resistant Hypertension Using Lifestyle Modification to Promote Health
This study will examine the effects of lifestyle intervention on fitness, dietary habits, and
body weight in patients with resistant hypertension (RH). Patients will be randomized to
either a 4-month adjunctive lifestyle intervention designed to lower BP that will be
delivered in a center-based CR program (C-LIFE), or to standardized education and physician
advice (SEPA) designed to promote the same healthy behaviors and reflecting the current
highest possible standard of care for promoting a healthy lifestyle in RH.
body weight in patients with resistant hypertension (RH). Patients will be randomized to
either a 4-month adjunctive lifestyle intervention designed to lower BP that will be
delivered in a center-based CR program (C-LIFE), or to standardized education and physician
advice (SEPA) designed to promote the same healthy behaviors and reflecting the current
highest possible standard of care for promoting a healthy lifestyle in RH.
The term resistant hypertension (RH) is defined as clinic blood pressure (BP) that remains
above goal (e.g., systolic blood pressure [SBP]>140 mm Hg and/or diastolic blood pressure
[DBP]>90 mm Hg), despite adherence to a regimen of 3 or more antihypertensive medications of
different classes, one of which is a diuretic.
With the growing prevalence of hypertension (HTN) in this country, RH is a major public
health concern, affecting more than 7.5 million Americans. Patients with RH are 50% more
likely to experience a CVD event, including stroke, kidney failure, myocardial infarction,
and death, compared to patients with controlled BP. There is an urgent need for developing RH
management strategies to lower BP as well as to reduce the high risk of CVD-related events.
Lifestyle modifications, including exercise training and dietary modification, are of proven
efficacy in lowering BP in unmedicated patients with HTN and are often recommended as the
first step for treating high BP. The Dietary Approaches to Stop Hypertension (DASH) diet has
been shown to lower BP in HTN patients who are not treated with drugs. Moreover, when the
DASH diet is combined with exercise and caloric restriction, even greater, and quite marked,
BP reductions can be achieved. However, the efficacy of these lifestyle modifications in HTN
patients who are refractory to medical therapy is unknown. This application aims to build
upon evidence supporting the value of lifestyle modifications in unmedicated patients with
HTN by proposing a randomized clinical trial (RCT) that will evaluate whether an intensive,
medically-supervised lifestyle intervention can successfully lower BP in medicated patients
with RH.
above goal (e.g., systolic blood pressure [SBP]>140 mm Hg and/or diastolic blood pressure
[DBP]>90 mm Hg), despite adherence to a regimen of 3 or more antihypertensive medications of
different classes, one of which is a diuretic.
With the growing prevalence of hypertension (HTN) in this country, RH is a major public
health concern, affecting more than 7.5 million Americans. Patients with RH are 50% more
likely to experience a CVD event, including stroke, kidney failure, myocardial infarction,
and death, compared to patients with controlled BP. There is an urgent need for developing RH
management strategies to lower BP as well as to reduce the high risk of CVD-related events.
Lifestyle modifications, including exercise training and dietary modification, are of proven
efficacy in lowering BP in unmedicated patients with HTN and are often recommended as the
first step for treating high BP. The Dietary Approaches to Stop Hypertension (DASH) diet has
been shown to lower BP in HTN patients who are not treated with drugs. Moreover, when the
DASH diet is combined with exercise and caloric restriction, even greater, and quite marked,
BP reductions can be achieved. However, the efficacy of these lifestyle modifications in HTN
patients who are refractory to medical therapy is unknown. This application aims to build
upon evidence supporting the value of lifestyle modifications in unmedicated patients with
HTN by proposing a randomized clinical trial (RCT) that will evaluate whether an intensive,
medically-supervised lifestyle intervention can successfully lower BP in medicated patients
with RH.
Inclusion Criteria:
- Documented resistant hypertension (RH). In the absence of a specific RH diagnosis,
individuals being treated for two or more weeks with 3 antihypertensive medications of
different classes, including a diuretic if tolerated, with clinic SBP ≥ 130 mm Hg or
DBP ≥ 80 mm Hg, will be eligible. Individuals being treated with 4 or more
antihypertensive medications, including a diuretic if tolerated, with SBP ≥ 120 or DBP
≥ 80 mm Hg will also be eligible.
- Adherent to prescribed medications
- Overweight (BMI ≥ 25 kg/m2)
- Sedentary
- Willing to be randomized to one of the 2 treatment groups and able to fully
participate in intervention
- Informed consent
Exclusion Criteria:
- Secondary HTN, non-adherence to anti-HTN medications
- Severe CKD (eGFR <40 ml/min/1.73m2)
- Severe ischemic heart disease (CCS Class 3 or 4 angina or evidence of ischemia at <85%
heart rate reserve on treadmill testing)
- Severe heart failure (NYHA association Class 3 or 4), high grade arrhythmias, severe
valvular heart disease
- Severe asthma or chronic obstructive lung disease
- Diabetes requiring insulin
- Musculoskeletal or neurologic problems that would preclude participation in aerobic
exercise training
- Major psychiatric disorder, a history of drug abuse, alcohol consumption >14
drinks/week
- Life-limiting comorbid medical condition such as cancer
- Prior gastric bypass surgery
- Currently pregnant
- Cognitively impaired
We found this trial at
1
site
2301 Erwin Rd
Durham, North Carolina 27710
Durham, North Carolina 27710
919-684-8111
Principal Investigator: James A. Blumenthal, Ph.D.
Phone: 919-684-3828
Duke Univ Med Ctr As a world-class academic and health care system, Duke Medicine strives...
Click here to add this to my saved trials